3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
8
Multiple Myeloma
4
Glioma
4
Thyroid Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Interventions
Specimen Handling
5
Biopsy
5
Whole-Body Irradiation
3
Mycophenolic Acid
3
Cyclosporine
3
Cyclophosphamide
3
Azacitidine
3
venetoclax
2
ruxolitinib
2
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Melphalan
2
Injections
2
Granulocyte Colony-Stimulating Factor
2
Decitabine
2
Busulfan
2
veliparib
1
tocilizumab
1
tagraxofusp
1
posaconazole
1
peginterferon alfa-2b
1
iadademstat
1
gilteritinib
1
fludarabine
1
fedratinib
1
axatilimab
1
Tranexamic Acid
1
Topotecan
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
dabrafenib
×
90 days
×
Clear all
No trials found.